Search clinical trials for: Checkpoint Inhibitor, Immune

Total 65023 results

Eikon Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Tumor, Solid

United States
Pierre Fabre Medicament

Terminated

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

France, Spain
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Solid Tumors

United States, Spain, Belgium, Denmark, Canada, Australia
Replimune Inc.
Bristol-Myers Squibb

Active, not recruiting

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Advanced Solid Tumor

United States, United Kingdom, Spain, Greece, France
RAPT Therapeutics, Inc.

Terminated

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Advanced Melanoma

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin Lymphoma | Primary Central Nervous System Lymphoma | Gray-zone Lymphoma

United States
Hecheng Li M.D., Ph.D

Completed

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus (PALACE-1)

Esophageal Squamous Cell Carcinoma

China
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (IMMUTACE)

Carcinoma, Hepatocellular | Hepatocellular Cancer | Hepatic Carcinoma

Germany
University Hospital, Basel, Switzerland
St. Clara Research Ltd.

Terminated

Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

Metastatic Pancreatic Cancer

Switzerland
Dr Tan-to CHEUNG

Completed

Neoadjuvant Anti-PD1 in HCC

HCC | Hepatocellular Carcinoma | Liver Cancer

Hong Kong
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Healthy Subjects

China
National Taiwan University Hospital
Novartis

Active, not recruiting

Ribociclib and Spartalizumab in R/M HNSCC (RISE-HN)

Head and Neck Squamous Cell Carcinoma

Taiwan
UNICANCER

Completed

Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck (NISCAHN)

Metastatic Cancer | Salivary Gland Carcinoma | Recurrent Cancer

France
Medical University of South Carolina
Bristol-Myers Squibb

Completed

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Oral Cavity SCC

United States
Seoul National University Hospital
Seoul National University Bundang Hospital; Korean Cancer Study Group (KCSG); Eisai Korea Inc... and other collaborators

Active, not recruiting

Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer (KORNELIA)

Metastatic Breast Cancer

Korea, Republic of
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC (FORCE)

Metastatic Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Lung Adenocarcinoma Metastatic | Large Cell Lung Carcinoma Metastatic

Germany
Novartis Pharmaceuticals

Completed

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Italy, Singapore, Canada, Israel, Korea, Republic of, Netherlands, Australia
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Mel-Ipi-Rx)

Malignant Melanoma

France
Memorial Sloan Kettering Cancer Center

Completed

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Breast Cancer | Invasive Adenocarcinoma of the Breast

United States
Bristol-Myers Squibb
JSS Medical Research Inc.

Completed

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Melanoma

Venezuela
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

Kidney Cancer

United States
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Skin Cancer | Melanoma (Skin) | Skin Carcinoma | Skin Melanoma

United States
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
Peking Union Medical College Hospital

Not yet recruiting

TIME in Immunotherapy Combined With nCRT for Rectal Cancer (TIMENT-R)

Locally Advanced Rectal Cancer
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Non-small Cell Lung Cancer

United States
Imperial College London
Cancer Research UK

Recruiting

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Disease | Gestational Trophoblastic Tumor, Recurrent

United Kingdom
University College, London
University College London Hospitals; Merck Sharp & Dohme LLC; University of Leeds and other collaborators

Recruiting

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC)

Adenocarcinoma of the Colon

United Kingdom
M.D. Anderson Cancer Center

Recruiting

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Thyroid

United States
Abramson Cancer Center at Penn Medicine

Recruiting

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Non Hodgkin Lymphoma

United States
Greg Durm, MD
Merck Sharp & Dohme LLC

Recruiting

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

NSCLC, Stage I

United States
University College, London
Bristol-Myers Squibb

Terminated

A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma (NeAT Glio)

Glioblastoma

United Kingdom
Bristol-Myers Squibb

Completed

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Upper Gastrointestinal Cancer

Canada
University of Utah
Bristol-Myers Squibb

Active, not recruiting

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

Bladder Cancer

United States
Gruppo Oncologico Italiano di Ricerca Clinica
Iqvia Pty Ltd; AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations... and other collaborators

Completed

Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE)

Non-Small Cell Lung Cancer

Italy
Hoffmann-La Roche

Completed

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Non-Small Cell Lung Cancer (NSCLC)

Germany
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Completed

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN)

Non-small Cell Lung Cancer (NSCLC)

Germany
Novartis Pharmaceuticals

Terminated

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Solid Tumors

United States, Germany, Spain, Belgium, Korea, Republic of, Japan, Italy
Alliance Foundation Trials, LLC.
Bristol-Myers Squibb

Terminated

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Multiple Sclerosis | Autoimmune Diseases | Rheumatoid Arthritis | Systemic Lupus Erythematosus | Psoriasis | Crohn Disease | Ulcerative Colitis | Non-small Cell Lung Cancer | Giant Cell Arteritis | Polymyalgia Rheumatica

United States
Assistance Publique - Hôpitaux de Paris

Suspended

Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (METIMGAST)

Gastric Adenocarcinoma | Oesophageal Adenocarcinoma

France
Bristol-Myers Squibb
PPD

Completed

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (Checkmate 171)

Non-Small Cell Lung Cancer

Poland, Spain, Austria, Denmark, Finland, Greece, Hungary, Ireland, Portugal, Romania, Russian Federation, Sweden, United Kingdom
Bristol-Myers Squibb

Completed

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Encephalitis

United States
Gruppo Oncologico Italiano di Ricerca Clinica

Completed

Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma (NIVES)

Renal Cancer Metastatic

Italy
Yonsei University

Active, not recruiting

A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

Korea, Republic of
UNICANCER
Bristol-Myers Squibb

Completed

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen (NIVOREN)

Metastatic Renal Cell Carcinoma

France
Korean Cancer Study Group

Unknown

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Metastatic Solid Tumor | DDR Gene Mutation

Korea, Republic of
Samsung Medical Center
Ono Pharmaceutical Co. Ltd

Unknown

Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Duke University

Completed

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Unresectable Melanoma

United States
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)

Stage III (Unresectable) or Stage IV Advanced Melanoma

United States, Canada, Argentina, Colombia, Peru, Brazil
Hunan Cancer Hospital
Xiangya Hospital of Central South University; Innovent Biologics (Suzhou) Co...

Unknown

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

China

Search clinical trials for: Checkpoint Inhibitor, Immune

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations